Evidence that activation of nuclear factor-κB is essential for the cytotoxic effects of doxorubicin and its analogues

Biochemical Pharmacology

Volumn 67, Issue 2, 2004, Pages 353-364

  Ashikawa, Kazuhiro ^a   Shishodia, Shishir ^a   Fokt, Izabel ^a   Priebe, Waldemar ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytotoxicity; Doxorubicin; NBD peptide; NF B; RIP; Transcription factor

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYTOTOXIC AGENT; DOXORUBICIN; DOXORUBICIN DERIVATIVE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEPTIDE; PYRROLIDINE DITHIOCARBAMATE; UNCLASSIFIED DRUG; WP 631; WP 744;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPATHOGENIC EFFECT; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; LYMPHOID CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 1642579534     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.08.039     Document Type: Article

References (51)

1. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57:1999;727-741.
2. Pinedo H.M., Peters G.F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol. 6:1988;1653-1664.
3. Jordan A., Hadfield J.A., Lawrence N.J., McGown A.T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev. 18:1998;259-296.
4. Bose R., Verheij M., Haimovitz-Friedman A., Scotto K., Fuks Z., Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell. 82:1995;405-414.
5. Lorenzo E., Ruiz-Ruiz C., Quesada A.J., Hernandez G., Rodriguez A., Lopez-Rivas A., Redondo J.M. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J. Biol. Chem. 277:2002;10883-10892.
6. Hickman J.A. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev. 2:1992;121-139.
7. Piret B., Piette J. Topoisomerase poisons activate the transcription factor NF-kappa B in ACH-2 and CEM cells. Nucleic Acids Res. 24:1996;4242-4248.
8. Das K.C., White C.W. Activation of NF-kappa B by antineoplastic agents. Role of protein kinase C. J. Biol. Chem. 272:1997;14914-14920.
9. Manna S.K., Zhang H.J., Yan T., Oberley L.W., Aggarwal B.B. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J. Biol. Chem. 273:1998;13245-13254.
10. Baeuerle P.A., Baichwal V.R. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv. Immunol. 65:1997;111-137.
11. Baldwin A.S. Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14:1996;649-683.
12. Beg A.A., Ruben S.M., Scheinman R.I., Haskill S., Rosen C.A., Baldwin A.S. Jr. I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention. Genes Dev. 6:1992;1899-1913.
13. Beg A.A., Finco T.S., Nantermet P.V., Baldwin A.S. Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation. Mol. Cell Biol. 13:1993;3301-3310.
14. Pahl H.L. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene. 18:1999;6853-6866.
15. Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274:1996;782-784.
16. Wang C.Y., Mayo M.W., Baldwin A.S. Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappa B. Science. 274:1996;784-787.
17. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappa B. Science. 274:1996;787-789.
18. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. Jr. NF-kappa B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 281:1998;1680-1683.
19. Wang C.Y., Guttridge D.C., Mayo M.W., Baldwin A.S. Jr. NF-kappa B induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell Biol. 19:1999;5923-5929.
20. Patel N.M., Nozaki S., Shortle N.H., Bhat-Nakshatri P., Newton T.R., Rice S., Gelfanov V., Boswell S.H., Goulet R.J. Jr., Sledge G.W. Jr., Nakshatri H. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappa B is enhanced by Ikappa Balpha super-repressor and parthenolide. Oncogene. 19:2000;4159-4169.
21. Wang C.Y., Cusack J.C. Jr., Liu R., Baldwin A.S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappa B. Nat. Med. 5:1999;412-417.
22. Cusack J.C., Liu R., Baldwin A.S. NF-kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappa B. Drug. Resist. Updat. 2:1999;271-273.
23. Cusack J.C. Jr., Liu R., Houston M., Abendroth K., Elliott P.J., Adams J., Baldwin A.S. Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 61:2001;3535-3540.
24. Santos-Silva M.C., Sampaio de Freitas M., Assreuy J. Killing of lymphoblastic leukemia cells by nitric oxide and taxol: involvement of NF-kappa B activity. Cancer Lett. 173:2001;53-61.
25. Shishodia S., Aggarwal B.B. Nuclear factor-κB activation: a question of life and death. J. Biochem. Mol. Biol. 35:2002;28-40.
26. Mayo M.W., Wang C.Y., Cogswell P.C., Rogers-Graham K.S., Lowe S.W., Der C.J., Baldwin A.S. Jr. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic. Ras. Sci. 278:1997;1812-1815.
27. Segev D.L., Hoshiya Y., Stephen A.E., Hoshiya M., Tran T.T., MacLaughlin D.T., Donahoe P.K., Maheswaran S. Mullerian inhibiting substance regulates NF-kappa B signaling and growth of mammary epithelial cells in vivo. J. Biol. Chem. 276:2001;26799-26806.
28. Segev D.L., Ha T.U., Tran T.T., Kenneally M., Harkin P., Jung M., MacLaughlin D.T., Donahoe P.K., Maheswaran S. Mullerian inhibiting substance inhibits breast cancer cell growth through an NF-kappa B-mediated pathway. J. Biol. Chem. 275:2000;28371-28379.
29. Huang Y., Johnson K.R., Norris J.S., Fan W. Nuclear factor-kappa B/I kappa B signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res. 60:2000;4426-4432.
30. Boland M.P., Foster S.J., O'Neill L.A. Daunorubicin activates NF-kappa B and induces kappa B-dependent gene expression in HL-60 promyelocytic and Jurkat T lymphoma cells. J. Biol. Chem. 272:1997;12952-12960.
31. Kalivendi S.V., Kotamraju S., Zhao H., Joseph J., Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J. Biol. Chem. 276:2001;47266-47276.
32. Arlt A., Vorndamm J., Breitenbroich M., Folsch U.R., Kalthoff H., Schmidt W.E., Schafer H. Inhibition of NF-kappa B sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene. 20:2001;859-868.
33. Bottero V., Busuttil V., Loubat A., Magne N., Fischel J.L., Milano G., Peyron J.F. Activation of nuclear factor-kappa B through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res. 61:2001;7785-7791.
34. Bian X., McAllister-Lucas L.M., Shao F., Schumacher K.R., Feng Z., Porter A.G., Castle V.P., Opipari A.W. Jr. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J. Biol. Chem. 276:2001;48921-48929.
35. Martin B., Vaquero A., Priebe W., Portugal J. Bisanthracycline WP631 inhibits basal and Sp1-activated transcription initiation in vitro. Nucleic Acids Res. 27:1999;3402-3409.
36. Faderl S., Estrov Z., Kantarjian H.M., Harris D., Van Q., Fokt I., Przewloka T., Godlewski C., Woynarowski J.M., Priebe W. WP744, a novel anthracycline with enhanced proapoptotic and antileukemic activity. Anticancer Res. 21:2001;3777-3784.
37. May M.J., D'Acquisto F., Madge L.A., Glockner J., Pober J.S., Ghosh S. Selectiveinhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science. 289:2000;1550-1554.
38. Stanger B.Z., Leder P., Lee T.H., Kim E., Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 81:1995;513-523.
39. Ting A.T., Pimentel-Muinos F.X., Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappa B but not Fas/APO-1-initiated apoptosis. EMBO J. 15:1996;6189-6196.
40. Chaturvedi M.M., Mukhopadhyay A., Aggarwal B.B. Assay for redox sensitive transcription factors. Methods Enzymol. 319:2000;585-601.
41. Totpal K., LaPushin R., Kohno T., Darnay B.G., Aggarwal B.B. TNF and its receptor antibody agonist differ in mediation of cellular responses. J. Immunol. 153:1994;2248-2257.
42. Haridas V., Darnay B.G., Natarajan K., Heller R., Aggarwal B.B. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation. J. Immunol. 160:1998;3152-3162.
43. Beg A.A., Baldwin A.S. Jr. Activation of multiple NF-kappa B/Rel DNA-binding complexes by tumor necrosis factor. Oncogene. 9:1994;1487-1492.
44. Bonizzi G.J., Piette M.P., Merville V., Bours V. Distinct signal transduction pathways mediate nuclear factor-kB induction by IL-1 beta in epithelial and lymphoid cells. J. Immunol. 159:1997;5264.
45. Tergaonkar V., Pando M., Vafa O., Wahl G., Verma I. p53 stabilization is decreased upon NF-kappa B activation: a role for NF-kappa B in acquisition of resistance to chemotherapy. Cancer Cell. 1:2002;493-503.
46. Lavon I., Pikarsky E., Gutkovich E., Goldberg I., Bar J., Oren M., Ben-Neriah Y. Nuclear factor-kappa B protects the liver against genotoxic stress and functions independently of p53. Cancer Res. 63:2003;25-30.
47. Panet H., Barzilai A., Daily D., Melamed E., Offen D. Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J. Neurochem. 77:2001;391-398.
48. Schneider A., Martin-Villalba A., Weih F., Vogel J., Wirth T., Schwaninger M. NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat. Med. 5:1999;554-559.
49. Ryan K.M., Ernst M.K., Rice N.R., Vousden K.H. Role of NF-kappa B in p53-mediated programmed cell death. Nature. 404:2000;892-897.
50. Wu H., Lozano G. NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. J. Biol. Chem. 269:1994;20067-20074.
51. Kuhnel F., Zender L., Paul Y., Tietze M.K., Trautwein C., Manns M., Kubicka S. NF-kappa B mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem. 275:2000;6421-6427.